Vanda Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Vanda Pharmaceuticals
VNDA Stock  USD 6.10  0.10  1.61%   
Vanda Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Vanda Pharmaceuticals' valuation are provided below:
Gross Profit
203.1 M
Profit Margin
(1.02)
Market Capitalization
366.5 M
Enterprise Value Revenue
0.5032
Revenue
216.1 M
We have found one hundred twenty available fundamental trend indicators for Vanda Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Vanda Pharmaceuticals current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. As of February 19, 2026, Market Cap is expected to decline to about 409.6 M. In addition to that, Enterprise Value is expected to decline to about 354.2 M

Vanda Pharmaceuticals Total Revenue

147.15 Million

Check Vanda Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vanda Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.5 M, Interest Expense of 6 M or Total Revenue of 147.2 M, as well as many indicators such as Price To Sales Ratio of 2.28, Dividend Yield of 0.0 or PTB Ratio of 1.51. Vanda financial statements analysis is a perfect complement when working with Vanda Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Vanda Stock
Check out the analysis of Vanda Pharmaceuticals Correlation against competitors.
For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.

Vanda Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets315.4 M488.9 M350.9 M
Slightly volatile
Short and Long Term Debt Total11 M15.6 M12.8 M
Pretty Stable
Other Current Liabilities141.4 M134.7 M57.2 M
Slightly volatile
Total Current Liabilities152.4 M145.2 M65.2 M
Slightly volatile
Total Stockholder Equity224.5 M327.2 M262.8 M
Slightly volatile
Other Liabilities5.8 M6.1 M22.7 M
Slightly volatile
Property Plant And Equipment Net14.2 M13.5 M7.7 M
Slightly volatile
Accounts Payable4.1 M4.9 M4.4 M
Slightly volatile
Cash75.1 M84.9 M70.3 M
Slightly volatile
Non Current Assets Total148.8 M141.7 M84.5 M
Slightly volatile
Non Currrent Assets Other11.6 M11.1 M5.2 M
Slightly volatile
Other Assets103.1 M98.2 M43.4 M
Slightly volatile
Cash And Short Term Investments221.8 M263.8 M238.8 M
Slightly volatile
Common Stock Total Equity39.5 K65.5 K44.4 K
Slightly volatile
Common Stock Shares Outstanding64.4 M58.9 M72.9 M
Slightly volatile
Liabilities And Stockholders Equity315.4 M488.9 M350.9 M
Slightly volatile
Non Current Liabilities Total28 M16.6 M28.3 M
Slightly volatile
Other Current Assets28.3 M27 M11.4 M
Slightly volatile
Other Stockholder Equity476.6 M721.3 M511.3 M
Slightly volatile
Total Liabilities90.9 M161.8 M88.2 M
Slightly volatile
Property Plant And Equipment Gross27.4 M26.1 M10 M
Slightly volatile
Total Current Assets249 M347.3 M271.3 M
Slightly volatile
Short Term Debt5.3 M5.6 M8 M
Pretty Stable
Common Stock42.9 K59 K44.3 K
Slightly volatile
Property Plant Equipment3.5 M3 M3.7 M
Slightly volatile
Short Term Investments161.4 M179 M169.9 M
Slightly volatile
Net Receivables57.3 M54.6 M24 M
Slightly volatile
Intangible Assets122.9 M117.1 M43.1 M
Slightly volatile
Net Tangible Assets614.2 M584.9 M285.1 M
Slightly volatile
Capital Surpluse578 M789.2 M539.6 M
Slightly volatile
Long Term Investments15.2 M17.1 M18.7 M
Slightly volatile
Long Term Debt Total20 M22.5 M24.6 M
Slightly volatile
Non Current Liabilities Other10 M9.5 M7.6 M
Slightly volatile
Net Invested Capital453.9 M327.2 M299.3 M
Slightly volatile
Short and Long Term Debt21.6 M24.3 M26.5 M
Slightly volatile
Net Working Capital330.2 M202.1 M219.3 M
Slightly volatile
Capital Stock61.7 K59 K54.5 K
Slightly volatile
Capital Lease Obligations9.8 M12.6 M13.4 M
Slightly volatile

Vanda Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization12.5 M11.9 M5 M
Slightly volatile
Total Revenue147.2 M216.1 M148 M
Slightly volatile
Gross Profit133.8 M203.1 M134.8 M
Slightly volatile
Other Operating Expenses385.6 M367.3 M178.9 M
Slightly volatile
Research Development114.7 M109.3 M53.6 M
Slightly volatile
Cost Of Revenue18.7 M13 M20.5 M
Pretty Stable
Total Operating Expenses371.9 M354.2 M165.7 M
Slightly volatile
Total Other Income Expense Net13.1 M12.5 M5.2 M
Slightly volatile
Selling General Administrative249.8 M238 M107.1 M
Slightly volatile
Non Operating Income Net Other368.8 K414.9 K452.9 K
Slightly volatile
Selling And Marketing Expenses2.9 M1.7 M3.8 M
Pretty Stable
Reconciled Depreciation12.5 M11.9 M4.3 M
Slightly volatile

Vanda Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow71.3 M102.8 M67.2 M
Slightly volatile
Capital Expenditures948.1 K998 K2.9 M
Very volatile
End Period Cash Flow75.2 M85.3 M70.5 M
Slightly volatile
Stock Based Compensation9 M9.5 M370.2 M
Slightly volatile
Exchange Rate Changes25.3 K46 K25.5 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.282.40517.9 K
Slightly volatile
PTB Ratio1.511.588619.9997
Slightly volatile
Days Sales Outstanding62.9992.181960.6538
Very volatile
Book Value Per Share3.255.55214.9555
Slightly volatile
Average Payables1.7 M1.8 M1.6 M
Slightly volatile
Stock Based Compensation To Revenue0.04160.04380.2193
Slightly volatile
PB Ratio1.511.588619.9997
Slightly volatile
EV To Sales1.982.08487.9 K
Slightly volatile
Inventory Turnover11.087.043212.8668
Slightly volatile
Days Of Inventory On Hand49.2351.8231196
Slightly volatile
Payables Turnover2.512.64055.2337
Pretty Stable
Sales General And Administrative To Revenue1.010.840.9541
Slightly volatile
Average Inventory1.9 M1.8 M1.9 M
Slightly volatile
Research And Ddevelopement To Revenue0.480.505613.3124
Slightly volatile
Capex To Revenue0.00440.00460.7443
Slightly volatile
Cash Per Share3.634.47734.8564
Slightly volatile
Days Payables Outstanding210138212
Slightly volatile
Intangibles To Total Assets0.250.23950.1087
Slightly volatile
Current Ratio2.272.39225.5437
Slightly volatile
Tangible Book Value Per Share2.793.56524.2424
Slightly volatile
Receivables Turnover3.763.95969.3048
Slightly volatile
Shareholders Equity Per Share3.255.55214.9555
Slightly volatile
Debt To Equity0.05010.04770.0327
Very volatile
Capex Per Share0.01610.01690.0642
Pretty Stable
Average Receivables919.2 K1.7 M1.8 M
Very volatile
Revenue Per Share2.153.66712.8866
Slightly volatile
Interest Debt Per Share0.280.26490.2391
Pretty Stable
Debt To Assets0.01630.03190.0258
Slightly volatile
Graham Number3.343.527.1906
Pretty Stable
Operating Cycle197144182
Slightly volatile
Price Book Value Ratio1.511.588619.9997
Slightly volatile
Days Of Payables Outstanding210138212
Slightly volatile
Company Equity Multiplier2.971.49442.4788
Slightly volatile
Long Term Debt To Capitalization0.00720.00820.0089
Slightly volatile
Total Debt To Capitalization0.04780.04550.0316
Very volatile
Debt Equity Ratio0.05010.04770.0327
Very volatile
Quick Ratio2.262.37955.4923
Slightly volatile
Net Income Per E B T0.881.59021.1021
Very volatile
Cash Ratio0.560.58452.1379
Slightly volatile
Days Of Inventory Outstanding49.2351.8231196
Slightly volatile
Days Of Sales Outstanding62.9992.181960.6538
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.11.00911.0119
Very volatile
Price To Book Ratio1.511.588619.9997
Slightly volatile
Fixed Asset Turnover16.9415.991221.0042
Very volatile
Debt Ratio0.01630.03190.0258
Slightly volatile
Price Sales Ratio2.282.40517.9 K
Slightly volatile
Asset Turnover0.290.4420.3917
Slightly volatile
Gross Profit Margin0.70.93960.8711
Pretty Stable
Price Fair Value1.511.588619.9997
Slightly volatile

Vanda Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap409.6 M467.8 M549.7 M
Pretty Stable
Enterprise Value354.2 M405.5 M486.5 M
Pretty Stable

Vanda Fundamental Market Drivers

Forward Price Earnings103.0928
Cash And Short Term Investments263.8 M

Vanda Upcoming Events

14th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Vanda Pharmaceuticals Financial Statements

Vanda Pharmaceuticals stakeholders use historical fundamental indicators, such as Vanda Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Vanda Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Vanda Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Vanda Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Vanda Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-5.2 M-5 M
Total Revenue216.1 M147.2 M
Cost Of Revenue13 M18.7 M
Stock Based Compensation To Revenue 0.04  0.04 
Sales General And Administrative To Revenue 0.84  1.01 
Research And Ddevelopement To Revenue 0.51  0.48 
Revenue Per Share 3.67  2.15 
Ebit Per Revenue(0.70)(0.73)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Vanda Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vanda Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vanda Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vanda Pharmaceuticals Stock:
How To Invest In Vanda
Details
Is Vanda Stock a good investment?
Details
What is Vanda Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Vanda Pharmaceuticals Correlation against competitors.
For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vanda Pharmaceuticals. If investors know Vanda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Vanda Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
(0.96)
Earnings Share
(3.74)
Revenue Per Share
3.667
Quarterly Revenue Growth
0.076
Return On Assets
(0.17)
Understanding Vanda Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Vanda's accounting equity. The concept of intrinsic value - what Vanda Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Vanda Pharmaceuticals' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Vanda Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vanda Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Vanda Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY